Cipla Limited (NSE: CIPLA) and Laurus Labs Ltd (NSE: LAURUSLABS) are both listed in the Medicinal Chemicals and Botanical Products industry. Cipla has a market capitalisation of ₹1,12,054 Cr and Laurus Labs ₹1,26,865 Cr, as of 9 Nov 2026. Their P/E ratios are 28.9 and 142.7 respectively. Return on equity is 11.74% for Cipla and 17.74% for Laurus Labs. Over one year, Cipla's share price is down 7.1% and Laurus Labs's is up 151.6%.
| Metric | Cipla | Laurus Labs |
|---|---|---|
| NSE Symbol | CIPLA | LAURUSLABS |
| BSE Code | 500087 | 540222 |
| Share Price | ₹1,403.80 | ₹2,454.00 |
| Market Cap | ₹1,12,054 Cr | ₹1,26,865 Cr |
| P/E Ratio | 28.9 | 142.7 |
| Return on Equity | 11.74% | 17.74% |
| Return on Assets | 7.58% | 8.18% |
| Dividend Yield | 0.94% | 0.10% |
| Beta (1Y) | 0.01 | 0.47 |
| 1-Year Price Change | -7.1% | +151.6% |
| 3-Month Price Change | -4.4% | +32.4% |
| 52-Week Range | ₹1,165.70 – ₹1,539.70 | ₹944.90 – ₹2,480.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹7,404 Cr | ₹2,206 Cr |
| Quarterly Net Profit | ₹852 Cr | ₹436 Cr |
| Net Margin | 11.5% | 19.8% |
| EPS (Basic, Quarter) | ₹10.86 | ₹8.17 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respirator…
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions fo…
Laurus Labs has a market capitalisation of ₹1,26,865 Cr, against ₹1,12,054 Cr for Cipla as of 9 Nov 2026, about 1.1 times the size by market cap.
Cipla has a P/E of 28.9 and Laurus Labs a P/E of 142.7 as of 9 Nov 2026.
Cipla has a return on equity of 11.74% and Laurus Labs 17.74%.
Cipla's share price is down 7.1% over one year and Laurus Labs's is up 151.6%.
Cipla reported revenue of ₹7,404 Cr and net profit of ₹852 Cr for Q2 FY27. Laurus Labs reported revenue of ₹2,206 Cr and net profit of ₹436 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.